Arbor Biotechnologies is a genetic medicine company that claims to have the most extensive gene editing toolkit in the industry and is also establishing a substantial war fund.Company owned Raised $215 million In terms of financing, it is committed to advancing its main clinical testing projects.
The Series B financing announced on Tuesday was led by Temasek, Ally Bridge Group and TCG Crossover.
Arbor, located in Cambridge, Massachusetts, uses machine learning and artificial intelligence to mine its database of billions of proteins. Doing so allows the company to discover enzymes with potential uses in CRISPR gene editing. Cas9 is an enzyme called nuclease, probably the most famous of the cutting enzymes used in CRISPR editing. Arbor claims that it has discovered more than 60 nuclease families and more than 70 CRISPR transposases, another enzyme. Arbor’s CRISPR toolbox includes DNA nuclease, RNA nuclease, and transposase. The company uses these nucleases in its genetic drugs, which are designed to edit genetic errors that cause disease.
So far, Arbor is in the preclinical stage. The company’s main project is for liver and central nervous system diseases. In a prepared statement, Arbor CEO Devyn Smith stated that Arbor plans to use the new funding to advance these projects to clinical testing. The cash will also be used to advance the pipeline project and support further investment in its discovery technology.
“Although our main focus is on developing our custom CRISPR nucleases, we are also looking to advance our other precision editing innovations, such as CRISPR transposases,” Smith said.
The financing is the latest development in Arbor’s busy year.Company owned Brought a series of New staff, Including Smith, who Joined in April. The company’s business development has also made progress. In August, Vertex Pharmaceuticals signed a New partnership with Arbor, To expand the alliance that originally started in 2018.
Under the new agreement, Boston-based Vertex will use Arbor’s CRISPR gene editing technology to research and develop new in vitro cell therapies. Vertex’s primary desire is to design islet cells, which are cells in the pancreas that produce insulin, as a potential new treatment for type 1 diabetes. Vertex is also interested in developing blood disease treatments for sickle cell anemia and beta thalassemia. The advance payment to Arbor was not disclosed, but the two companies said that potential milestone payments could be as high as $1.2 billion.
The use of CRISPR in therapeutic applications has shifted to smaller cleavage enzymes, which leaves more room for Arbor’s additional cargo Publish The research on Cas13d stems from the company’s technology platform. This enzyme is part of the Cas13 family. Its small size makes it suitable for RNA manipulation and detection.
However, Arbor faces competition in the downsizing race, especially when biotech companies seek gene-editing therapies that work in patients. Mammoth Biosciences touts a toolbox containing Cas14 and CasPhi enzymes, both of which are smaller than Cas9.Located in South San Francisco Mammoth announced a $150 million Series D financing in September. At the end of last month, Mammoth and Apex announced a alliance Focus on the development of in vivo gene editing therapies for two undisclosed genetic diseases. The transaction paid the Mammoth US$41 million in advance, and another US$650 million related to the milestone.
Arbor was founded in 2016, based on MIT research. The biotech company raised $15.6 million in Series A financing in 2017. The latest financing adds new investors Arrowmark Partners, Deep Track Capital, Great Point Ventures, Illumina Ventures, Janus Henderson Investors, Logos Capital, Ono Venture Investment, Piper Heartland Healthcare Capital, Ridgeback Capital Investments, Section 32, Surveyor Capital, Funds managed by T. Rowe Price Associates, Tao Capital Partners, Tekla Capital Management, Woodline Partners, and undisclosed global investment funds. In addition, Vertex also invested in early investor ARCH Venture Partners.
Photos of Flickr users Jason Baker Through knowledge sharing license
